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Hepatitis C virus (HCV) is a major human pathogen causing mild to severe liver disease worldwide and is remarkably
efficient at establishing persistent infections. Previously, we have shown that the core protein has an immunomodulatory
function including the suppression of T lymphocyte responses to viral infection. To investigate the underlying mechanism for
the role of core protein in immune modulation, we examined the effect of core on the sensitivity of the human T cell line,
Jurkat, to Fas-mediated apoptosis. The transient and stable expression of core protein in Jurkat cells increased the sensitivity
of cells to Fas-mediated apoptosis when compared to control cells expressing vector DNA alone. In addition, we demon-
strated that the core protein binds to the cytoplasmic domain of Fas which may enhance the downstream signaling event of
Fas-mediated apoptosis. The expression of core protein did not alter the cell surface expression of Fas, indicating that the
increased sensitivity of core-expressing cells to Fas ligand was not due to upregulation of Fas. Furthermore, we observed
the augmentation of caspase-3 activity in core-expressing cells. These results suggest that the core protein may promote the
apoptosis of immune cells during HCV infection via the Fas signaling pathway, thus facilitating HCV persistence. © 2000
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INTRODUCTION
Fas, a member of the tumor necrosis factor receptor
(TNFR) family, triggers apoptosis by transmitting a death
signal through the cytoplasmic domain of Fas following
engagement with Fas ligand (FasL) (Nagata, 1997; Na-
gata and Golstein, 1995). Fas-mediated apoptosis plays
a crucial role in immune regulation through the periph-
eral deletion of self-reactive cells and activation-induced
T cell death (Nagata and Golstein, 1995). The down-
stream signaling cascade involved in Fas-mediated apop-
tosis is well-delineated through several lines of inves-
tigations (Nagata, 1997). The binding of FasL to Fas
leads to the activation of a cascade of proteases, known
as caspases, that directly leads to cell death. Several
components of the Fas-mediated apoptotic pathway
have been identified. Upon trimerization of Fas following
engagement with FasL, FADD is the first molecule re-
cruited to the cytoplasmic domain of the Fas within
Fas-bearing cells (Chinnaiyan et al., 1995). FADD in turn
recruits procaspase-8 via a death effector domain inter-
action and activates procaspase-8, thus linking the death
domains of early signaling proteins to activation of the
caspase cascade (Muzio et al., 1996). Activation of these
1 To whom correspondence and reprint requests should be ad-
ressed at Beirne Carter Center for Immunology Research, Box 801386,Sniversity of Virginia Health Sciences Center, Charlottesville, VA 22908-
386. Fax: (804) 924-1221. E-mail: ysh5e@virginia.edu.
127downstream caspases leads to cleavage of substrates
that include inhibitor of caspase-activated DNAse, which
activates caspase-activated DNAse, poly-ADP-ribose
polymerase, and numerous structural proteins including
lamin, actin, and fodrin (Enari et al., 1998; Kawahara et
al., 1998; Mukae et al., 1998; Sakahira et al., 1998).
Hepatitis C virus (HCV) is an enveloped positive-
strand RNA virus belonging to the family Flaviviridae
(Choo et al., 1989). HCV is a major cause of transfusion-
associated hepatitis prior to the development of sero-
logic tests for HCV-contaminated blood products and it
remains a major agent of community-acquired hepatitis
(Hollinger, 1990; Houghton et al., 1991). Characteristic
eatures of HCV infection include the high incidence of
ersistent infection with a high rate of progression to
hronic hepatitis (Hollinger, 1990). HCV persistent infec-
ion in the liver is strongly associated with the develop-
ent of hepatocellular carcinoma (HCC) (Saito et al.,
990). There is growing evidence that HCV can replicate
ithin peripheral blood mononuclear cells (PBMC) of
hronically infected patients besides hepatocytes, sug-
esting a potential mechanism for the high rate of HCV
ersistent infection and the immunological disease in-
uced by HCV infection (Bouffard et al., 1992; Bronowicki
t al., 1998; Muller et al., 1993; Zignego et al., 1992). Some
human lymphoid cell lines are susceptible to HCV infec-
tion in vitro (Ikeda et al., 1997; Mizutani et al., 1996;himizu et al., 1992, 1993). Furthermore, infection of ex-
trahepatic tissues is supported by the finding that the
0042-6822/00 $35.00
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from that in serum or PBMC (Cabot et al., 1997; Maggi et
al., 1997; Navas et al., 1998; Okuda et al., 1999; Afonso et
al., 1999).
The HCV RNA genome is approximately 9.5 kb in
length and encodes a single polyprotein (Houghton,
1996). This precursor protein is cleaved by the host and
viral proteases to generate three structural proteins at
the N-terminal end and six nonstructural proteins at the
C-terminal end (Hijikata et al., 1991; Houghton, 1996;
Ralston et al., 1993). The HCV core protein consists of
191 amino acids with an apparent molecular mass of 21
kDa. In addition to the viral capsid protein, the HCV core
protein has been shown to possess a number of regu-
latory functions for viral and cellular gene expression
(Ray et al., 1995, 1997; Shih et al., 1995; Srinivas et al.,
1996) as well as oncogenic potential (Ray et al., 1996a).
Recent studies indicate that it can enhance or suppress
apoptosis depending on transfection methods or cell
types or apoptosis-inducing agents. The stable expres-
sion of core protein enhances the apoptosis of hepato-
cyte cell lines, HepG2, by the Fas signaling pathway
(Ruggieri et al., 1997) and also increases TNF-a-induced
poptosis through the physical association between the
ore and the cytoplasmic domain of TNFR1 (Zhu et al.,
998). In contrast, the inhibition of Fas and TNF-a medi-
ted apoptosis of HepG2 cells was observed by tran-
ient expression of the core protein (Marusawa et al.,
999). Furthermore, the core protein suppresses apopto-
is in human cervical epithelial cells, HeLa, induced by
isplatin, in Chinese hamster ovary cells, CHO, by c-myc
verexpression, and in human breast carcinoma cells
ines, MCF7, by TNF-a (Ray et al., 1996b, 1998).
In this report, we demonstrate that the transient and
stable expression of HCV core protein increases the
sensitivity of human T lymphocyte lines, Jurkat, to Fas-
mediated apoptosis. Furthermore, we found that the HCV
core protein is physically associated with the cytoplas-
mic domain of the Fas molecule in vitro. This interaction
between the core and Fas leads to augmentation of the
activation of caspase-3 during Fas-mediated apoptosis.
These results suggest that the expression of core protein
in T lymphocytes may increase the physiologic turnover
of activated T lymphocytes during acute viral infection,
thus facilitating HCV persistence and subsequent virus
spread.
RESULTS
The HCV core protein increases the susceptibility
of the human lymphoid T cell line to Fas-mediated
cell death
Previously, we reported that the HCV core protein can
suppress host immune responses in a murine model
28 HAHwhen delivered via infection with a recombinant vaccinia
virus capable of expressing the core protein (Large et al.,
c
p1999). The suppression phenotype includes: (1) an in-
creased viral titer, (2) a reduced CTL activity with lower
CTL precursor frequency, and (3) a reduced level of IL-2
and IFN-g production. Based on these observations, we
ypothesize that the HCV core may modulate the cell
eath of immune cells such as T lymphocytes. To test
his possibility, we examined whether the expression of
he HCV core protein influences the sensitivity of T lym-
hocytes to cell death induced by Fas and FasL interac-
ion.
Jurkat cells were chosen to examine the effect of the
ore on Fas-mediated cell death since this cell line
xpresses high levels of cell surface Fas (Nagata and
olstein, 1995). Jurkat cells were transiently transfected
ith the HCV core plasmid (pCI:core) or an empty plas-
id as a control (pCI:neo) for 24 h. pCI:neo contains the
MV promoter for heterologous gene expression and the
eomycin phosphotransferase gene. The expression of
ore protein in transfected Jurkat cells was determined
y Western blot analysis using a HCV-core-specific an-
ibody (Fig. 1A).
Transiently transfected Jurkat cells were examined for
heir susceptibility to Fas-mediated cell death by co-
ncubation with L cell transfectants expressing FasL
L:FasL1) or an anti-sense FasL (L:FasL2) as a control
Wang et al., 1996). It has been reported that murine FasL
sed in our study induces Fas-mediated apoptosis of
oth human and murine cells (Nagata, 1997). As shown
n Fig. 1B, transient expression of the core protein in-
reased the susceptibility of Jurkat cells to Fas-mediated
FIG. 1. Increased susceptibility of core-expressing cells to Fas-
mediated cell death. (A) Expression of HCV core protein in Jurkat cells.
Jurkat cells were mock transfected (lane 1) or transfected with an empty
vector pCI:Neo (lane 2) or pCI:core (lane 3). Twenty-four hours after
transfection, the expression of core protein was examined by Western
blot analysis using HCV-core-specific antibody (anti-HCV peptide 716).
(B) Increased Fas-mediated cytotoxicity in core-expressing Jurkat cells.
The cells transfected with core or control plasmid DNA were labeled
with 51Cr and cocultured for 6 and 12 h with L:FasL1 cells or L:FasL2
cells. The percentage of specific lysis was measured by a standard
51Cr-release assay. The results are representative of three independent
xperiments.
AL.ell death compared to cells transfected with the control
lasmid. The level of transient transfection in this exper-
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A REGiment was 50–60% based on the expression of green
fluorescent protein (GFP) in plasmid pEGFP-transfected
cells under similar conditions (data not shown). This
indicates that the enhanced apoptosis of cells trans-
fected with the HCV core gene is possibly due to the
effect of HCV core protein on the increased susceptibility
of Fas-bearing cells to FasL.
To examine whether the core protein can increase the
sensitivity of another T cell line to Fas-mediated cell
death, HUT 78 cells (human T lymphoma line) were
transiently transfected with pCI:core or pCI:neo. Upon
treatment of these transfected T cells with FasL, cells
expressing the core protein exhibited the enhanced sus-
ceptibility to Fas-mediated cell death compared to cells
transfected with a control plasmid (data not shown).
Taken together, these results suggest that the HCV core
protein may modulate Fas-mediated cell death of T lym-
phocytes by altering the Fas signaling event.
It has been previously demonstrated that the HCV core
protein suppresses host immune responses to viral in-
fection including vaccinia-virus (VV)-specific CTL re-
sponse and production of IFN-g and IL-2 in mice (Large
t al., 1999). We hypothesize that the increased suscep-
ibility of core-expressing T lymphocytes to Fas-mediated
poptosis as described above may account for the sup-
ression of host immune response in mice expressing
he HCV core protein. To test this possibility, we inocu-
ated Fas-deficient lpr mice with recombinant VV ex-
pressing the HCV core protein (vHCV-C), structural pro-
teins (vHCV-S), and control protein (vSC11). As shown in
Fig. 2A, the mice infected with vHCV-C generated VV-
specific CTL response as efficiently as mice infected
with a control virus, vSC11. Consistent with the CTL
activity in core-expressing mice, the level of VV titer in
vHCV-C mice was as low as that in mice infected
with vSC11 (Fig. 2B). This suggests that the functional
FIG. 2. Resistant phenotypes of core-induced immune suppression
n lpr mice. (A) VV-specific CTL activity in lpr mice. lpr mice were
inoculated with 5 3 107 pfu of recombinant vaccinia viruses, vHCV-C,
vHCV-S, and vSC11, respectively. On day 5 of virus inoculation, primary
VV-specific CTL activity was measured on P815 target cells infected
with vSC11. (B) Vaccinia virus titer in liver tissue. The vaccinia virus titer
was determined on BSC 40 monkey kidney cells from liver tissues
harvested on day 5 after virus inoculation.
HCV CORE PROTEIN ASexpression of Fas is critical for core-induced immune
suppression.The HCV core protein is physically associated
with the cytoplasmic domain of Fas in vitro
To understand a potential mechanism involved in the
increased cell death of T lymphocytes induced by HCV
core protein, we examined whether the HCV core protein
can directly interact with Fas. Furthermore, the HCV core
protein was previously shown to interact with a cytoplas-
mic domain of other TNFR family members, lympho-
toxin-b receptor (LTbR), and TNFR1 (Matsumoto et al.,
997; Zhu et al., 1998). The potential interaction between
ore protein and Fas was examined in vitro by glutathi-
ne thiotransferase (GST) binding assay using a GST
usion protein of HCV core (GST–core) and in vitro trans-
ated and radiolabeled Fas. In vitro translated and radio-
abeled full-length core protein was used as a positive
ontrol since the core protein is known to oligomerize by
tself (Matsumoto et al., 1996).
Figure 3A shows the result of a GST fusion binding
ssay. As expected, GST–core (lane 7) but not GST alone
lane 4) binds to radiolabeled core protein (21 kDa). We
lso found that GST–core (lane 9) but not GST alone
lane 6) interacts with the Fas protein (43 kDa). This
ndicates that there is a potential interaction between the
CV core protein and Fas. Surprisingly, we did not detect
n interaction between the GST–core fusion protein and
FIG. 3. The in vitro interaction of the HCV core protein with Fas. (A)
Interaction between the GST core protein and radiolabeled Fas. The
core protein (lane 1), cytoplasmic domain of TNFR1 (lane 2), and Fas
(lane 3) are in vitro translated and radiolabeled with [35S]methionine for
GST binding assay. GST alone (lanes 4–6) or GST–core fusion protein
(lanes 7–9) was incubated with in vitro translated and radiolabeled core
(lanes 4, 7), TNFR1 (lanes 5, 8) or Fas (lanes 6, 9). Following incubation,
GST–core fusion protein was purified using glutathione–agarose beads
and separated on SDS–PAGE. Radiolabeled core or Fas binding to
GST–core fusion protein was detected by autoradiography. Size mark-
ers in kilodaltons are shown to the left of the autoradiogram. (B)
Far-Western analysis for the interaction of the core protein with Fas,
GST (lanes 1, 3, 5, 7) or GST–core fusion protein (lanes 2, 4, 6, 8) was
subjected to SDS–PAGE and transferred to nitrocellulose. The proteins
bound to the membrane were renatured and incubated with either
HRP-labeled anti-HCV core antibody (lanes 1, 2) or in vitro translated
and radiolabeled HCV core (lanes 3, 4), TNFR1 (lanes 5, 6), or Fas
129ULATOR OF APOPTOSIS(lanes 7, 8) and subjected to immunoblotting (lanes 1, 2) or autoradiog-
raphy (lanes 3–8).
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previously (see Discussion).
To confirm the results of these in vitro binding studies,
we performed Far-Western analysis (Matsumoto et al.,
1997) as shown in Fig. 3B. GST–core and GST were
separated by SDS–PAGE, transferred to a nitrocellulose
membrane, and renatured. Potential interactions be-
tween core protein and Fas as well as TNFR1 were
examined by incubating the membrane with radiolabeled
Fas, TNFR1, or HCV core as a positive control. The
presence of core protein on the membrane was con-
firmed by Western blot analysis using HCV-core-specific
antibody (lane 2). A band corresponding to the molecular
weight of the core protein (21 kDa) or GST–core (48 kDa)
was detected by incubation with core protein (lane 4) or
Fas (lane 8). Consistent with a GST protein binding as-
say, we did not detect an interaction between GST–core
and TNFR1 (lane 6).
To determine whether the extracellular or cytoplasmic
domain of Fas is required for the interaction with core
protein, we generated plasmids capable of expressing
the extracellular and cytoplasmic domains of Fas by
site-directed mutagenesis. These truncated forms of Fas
protein were examined for their ability to interact with the
core protein by GST binding assay. As a positive control,
we used radiolabeled core protein (21 kDa) and full-
length Fas (43 kDa) as described above. As shown in Fig.
4, we detected a radiolabeled band corresponding to the
core or full-length Fas protein. In addition, the core pro-
tein could specifically bind to the cytoplasmic domain of
Fas (20 kDa) but not to the extracellular domain of Fas
(22 kDa). It is notable that the intensity of the band for
interaction between the core protein and the cytoplasmic
domain of Fas is weaker than that of core and Fas,
possibly due to the stability of the truncated form of Fas.
FIG. 4. Binding of core protein to the cytoplasmic domain of Fas.
GST–core (lanes 1–4) was incubated with in vitro translated and radio-
labeled core (lane 1), the full-length Fas protein (lane 2), the cytoplas-
mic domain of Fas (lane 3), or the extracellular region of Fas (lane 4).
Following binding to glutathione resin and subsequent washing, sam-
ples were separated on SDS–PAGE and detected by autoradiography.
Size markers in kilodaltons are shown to the left of the autoradiogram.
130 HAHThis suggests that the HCV core protein is able to bind to
the cytoplasmic domain of Fas and this interaction may
m
imodulate Fas-mediated apoptosis by altering the Fas
signaling pathway.
HCV core protein facilitates the induction
of Fas-mediated apoptosis in Jurkat cells
To further examine the biological effect of the physical
association between the core protein and the cytoplas-
mic domain of Fas on Fas-mediated apoptosis, we gen-
erated stable transfectants of Jurkat cells expressing the
core protein under the control of the CMV promoter or
containing an empty vector as a control. Several stable
Jurkat transfectants have been established by limiting
dilution in medium containing G418. When the core ex-
pression in representative clones (C4, C6, C10) of stable
transfectants was examined by RT-PCR analysis, these
cell lines expressed core-specific mRNA. The level of
core-specific RNA in core transfectants was comparable
to that in peripheral blood monocytes isolated from HCV-
infected patients by RT-PCR analysis (data not shown).
To determine whether HCV core affects the differential
kinetics of Fas-mediated apoptosis, we examined a time
course of apoptosis induction by measuring chromo-
somal DNA degradation of Jurkat transfectants upon
Fas/FasL interaction. The flow cytometry analysis of
chromosomal DNA contents was performed to deter-
mine cellular DNA contents. The levels of Fas-mediated
apoptosis was determined at various time points (40, 50,
65, 100 min) after Fas/FasL engagement. Apoptotic cells
were first detected at 40 min after Fas/FasL engagement
(Fig. 5A). The expression of HCV core protein in Jurkat
cells enhances the kinetics for sensitivity of cells to
Fas-mediated apoptosis. In contrast, less than 3% of
apoptotic cells was observed when core transfectants
were incubated with L:FsasL2 cells.
To determine whether the core/Fas interaction specif-
ically increased the susceptibility of core-expressing
cells to Fas-mediated apoptosis, we further examined
the effect of core protein on Fas-independent apoptosis
by treating cells with chemotherapeutic agents, etopo-
side and 5-fluorouacil (5-FU). These reagents have been
reported to trigger the p53-dependent induction of apop-
tosis (Lowe et al., 1993). When Jurkat and its transfec-
ants expressing core protein were treated with various
oncentrations of etoposide for 24 h, the induction of
poptosis by etoposide was comparable to that of Jurkat
nd its transfectant expressing core protein (Fig. 5B). A
imilar result was obtained in cells treated with various
oncentrations of 5-FU (data not shown). These results
uggest that core protein does not affect Fas-inde-
endent apoptosis induction such as p53 activation.
In addition, we determined whether caspase activa-
ion is required for the increased Fas-mediated apopto-
is induced by core protein. As shown in Fig. 5C, Fas-
AL.ediated apoptosis in Jurkat and its transfectant was
nhibited in the presence of caspase-3 and caspase-8
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C10 (data not shown).
A REGinhibitors. This suggests that the effect of core protein on
increased Fas-mediated apoptosis upon Fas/FasL en-
gagement depends on the activation of both caspase-3
and caspase-8.
The HCV core induces the increased Fas-mediated
apoptosis through augmentation of caspase-3
activation
To investigate a potential mechanism involved in the
increased Fas-mediated apoptosis induced by the core
protein, we examined the downstream Fas signaling
event in core transfectants, since the physical associa-
tion of the core protein with the cytoplasmic domain of
Fas may alter the apoptotic signaling event. First, we
examined whether the interaction between the core and
the cytoplasmic domain of Fas may stabilize the cell
surface expression of Fas. The level of cell surface Fas
expression was determined in core transfectants by flow
cytometry and compared with that of control cell lines.
The level of cell surface Fas expression in core trans-
fectants (C4, C6, C10) is comparable to that in parental
Jurkat or control plasmid transfected cells (data not
shown). This suggests that the effect of core on in-
creased sensitivity of Jurkat cells to Fas-mediated apop-
tosis may not be due to the upregulation of cell surface
Fas expression. This implies that the physical associa-
tion between the core protein and Fas may facilitate the
activation of intracellular apoptosis signalining mole-
cules such as caspase cascade.
To test this possibility, we examined the effect of the
core protein on the activation of caspase cascade by
determining the activation of caspase-3 at various time
points upon Fas/FasL engagement. Caspase-3 is one of
the downstream caspases activated upon Fas/FasL en-
gagement and is responsible for activating several
apoptosis target proteins, including caspase-activated
DNAse (Enari et al., 1998). The activation of caspase-3
was determined by examining the cleavage of pro-
caspase-3 (32 kDa) at 30, 45, and 90 min after Fas/FasL
engagement. As shown in Fig. 6A, the level of pro-
caspase-3 (32 kDa) in core transfectant (C4, C6, C10) is
slightly lower than that in control cells (V) at 30 min after
Fas/FasL engagement, suggesting the enhanced activa-
tion of caspase-3 in core transfectants. Upon 45 min
post-Fas/FasL engagement, there was a dramatic de-
crease of procaspase-3 level in the core transfectants
compared to that in control cells. All procaspase-3 was
activated in both core transfectants and control cells 90
min post-Fas/FasL engagement. However, core transfec-
tants incubated with L:FasL2 showed a comparable level
f procaspase-3.
Consistent with the effect of core protein on caspase-3
ctivation, the enzymatic activity of caspase-3 was also
131ULATOR OF APOPTOSISFIG. 5. Increased Fas-mediated apoptosis in stable Jurkat trans-
fectants expressing core protein. (A) Time course of apoptosis
induction upon Fas/FasL engagement. Vector transfectant and three
independent stable transfectants (C4, C6, C10) expressing HCV core
under the control of a CMV promoter were examined for Fas-
mediated apoptosis. All experiments were performed in triplicate
and at least 104 cells were examined for cellular DNA contents.
ells containing less than diploid DNA contents were defined as
poptotic cells. Bar graph and error bar represent mean and stan-
ard deviations, respectively. Mean value combined from three
ndependent experiments are shown. (B) Effect of core protein on
toposide-independent apoptosis. Jurkat and its transfectants were
reated with various doses of etoposide for 24 h. The degree of
poptosis was examined by the flow cytometry analysis as de-
cribed above. (C) Inhibition of Fas-mediated apoptosis by inhibitors
pecific for caspase-3 and caspase-8 activity. Jurkat cells and its
ore transfectant, C6, were pretreated with vehicle (DMSO),
aspase-3 inhibitor (Cs3I), or caspase-8 inhibitor (Cs8I) for 10 min.
he effect of inhibitors on Fas-mediated induction of apoptosis is
easured by a method as described above (Fig. 4A). At least 20,000
ells were examined for each experiment. Mean and standard
eviation from four independent experiments are shown. Similar
HCV CORE PROTEIN ASigher in core transfectants than in a control cell when
aspase-3 activity was determined by cleavage of a
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N ETcolorimetric substrate of caspase-3 (Fig. 6B). In contrast,
incubation of core transfectants with L:FasL2 showed a
asal level of caspase-3 activity. This suggests that the
CV core protein augments the activation of caspase-3
nvolved in the Fas downstream signaling event.
DISCUSSION
One of the most important aspects of HCV infection is
ts ability to establish a persistent infection in hosts. In
arious reports, the incidence of this persistence in in-
ected subjects is as high as 80% (Houghton, 1996). In
CV-infected individuals, it is believed that T cell re-
ponses, including both CTL and helper T lymphocytes,
re crucial in preventing viral persistence (Chang et al.,
997; Koziel, 1997). In particular, the frequency of HCV-
pecific CTL in the peripheral blood from chronically
nfected patients appears to be quite low and the detec-
ion of CTL response in these patients requires multiple
FIG. 6. Augmentation of caspase-3 activation in core transfectants
pon Fas/FasL engagement. (A) Time course of caspase-3 activation
pon Fas/FasL interaction. Vector transfectant or three independent
lones of HCV core transfectants (C4, C6, C10) of Jurkat cells were
ncubated with L cells (L:FasL1, L:FasL2). Upon 30 min, 45 min, and 90
min after incubation, cells were collected, lysed, and analyzed for the
caspase-3 activation by determining the cleavage of procaspase-3.
Each lane represents total cell lysates from 2 3 105 cells. Data repre-
ent three independent experiments. (B) Caspase-3 activity in trans-
ected Jurkat cells upon incubation with L:FasL1 or L:FasL2, Jurkat
ransfectants were coincubated with either L:FasL1 or L:FasL2. Upon
0 or 45 min after coincubation with L:FasL1 or L:FasL2, core trans-
fectants (C4, C6, C10) of Jurkat cells or a control cell were collected,
lysed, and assayed for caspase-3 activity using a colorimetric substrate
of caspase-3. Ac-DEVD-pNA. Buffer alone and 10 U of purified
caspase-3 were also used for assay. The enzyme assay was performed
in duplicate and results are representative of two independent exper-
iments.
132 HAHeptide stimulations in vitro (Rehermann et al., 1996a,b).
e have previously reported that in an experimental
o
turine model using infection with both VV and SIN
ecombinants, the expression of HCV core protein sup-
ressed the host immune responses including CTL re-
ponse and production of IFN-g and IL-2 cytokines
gainst viral infection (Large et al., 1999).
In this report, we examined the effect of HCV core
rotein on the sensitivity of Jurkat cells to Fas-mediated
poptosis and the downstream signaling event of Fas-
ediated apoptosis. The transient and stable expression
f the core protein in Jurkat cells increased the sensitivity
f cells to Fas-mediated apoptosis compared to that in
he control vector-transfected cells. This increased Fas-
ediated apoptosis induced by the expression of core
rotein may play an important role in core-mediated
mmune suppression in vivo since lpr mice were resis-
ant for core-mediated immune suppression when they
ere infected with VV recombinant expressing the HCV
ore protein, as shown in Fig. 2. This suggests that the
unctional expression of Fas protein may be required for
ore-mediated immune suppression. In addition, we
ound a physical association between the core protein
nd the cytoplasmic domain of Fas in vitro. Biochemical
analysis of stable transfectants expressing the core pro-
tein revealed that the core protein augmented caspase-3
activation upon Fas/FasL engagement, possibly due to
its physical association with Fas. As a consequence, the
induction of apoptosis in core transfectants was more
rapid compared to that in vector-transfected cells.
It is notable that the intensity of the band for interac-
tion between the core and cytoplasmic domain of Fas is
much weaker than that of the core and full-length Fas
(Fig. 4). There are several possibilities for the weak
intensity of the band for the interaction between the core
and cytoplasmic domain of Fas. First, it might be due to
a limited number of methionine residues in the cytoplas-
mic domain of Fas (one methionine residue), which al-
lows weaker labeling of protein with radioactivity. Sec-
ond, the instability of the cytoplasmic domain of the Fas
may give rise to a weaker association with the core
protein as shown in other truncated proteins, demon-
strating the decreased stability of the protein (Var-
shavsky, 1992).
The HCV core protein is a major component of viral
nucleocapsid and also multifunctions as a transcrip-
tional regulator of various viral and cellular promoters,
potentially disturbing normal cellular function. The core
protein cooperates with the Ras oncogene and trans-
forms primary rat embryo fibroblasts (Ray, 1996a), pos-
sibly by regulation of the p53 tumor suppressor promoter
(Ray et al., 1997; Lu et al., 1999). Furthermore, the HCV
core protein has been shown to interact with the cyto-
plasmic domain of LTbR and TNFR1, members of the
TNFR family which play important roles in immune mod-
ulation (Matsumoto et al., 1997; Zhu et al., 1998). These
AL.bservations as well as potential nuclear localization of
he truncated form of the core protein (Hsieh et al., 1998;
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A REGLo et al., 1995) implicate the role of this HCV core protein
n the establishment of HCV persistence and the devel-
pment of HCC.
It is of interest that the HCV core protein used in our
tudy did not bind to the cytoplasmic domain of TNFR1 in
vitro in contrast to studies done by Zhu and colleagues
(Zhu et al., 1998). This discrepancy may be due to strain
differences between the HCV Taiwan strain (genotype
1b) in experiments by Zhu et al. (Zhu et al., 1998) and the
CV Hutchinson strain (genotype 1a) (Grakoui et al.,
993) in our experiment. Although the core protein is well
onserved among different HCV genotypes, there are six
mino acid differences between these two strains within
he putative binding region of the core protein (amino
cid residues 36–119 of the core protein mapped for
inding to the LTbR). Some of these changes are dra-
matic, such as Ser-53 to Trp, Arg-70 to Gln, Cys-91 to Leu,
and Ser-106 to Asn. It is also worth noting that two
substitutions at both Ser-53 and Ser-106 involve potential
Ser/Thr phosphorylation sites (Shih et al., 1995).
HCV, like other hepatitis viruses, is predominantly a
hepatotrophic virus. Nonetheless, several studies sug-
gest that the infection/replication of HCV can be de-
tected in both PBMC and bone marrow cells (Bouffard et
al., 1992; Muller et al., 1993). A recent study by
ronowicki and colleagues (Bronowicki et al., 1998)
trengthens the evidence for HCV replication in PBMC by
aking advantage of severe combined immunodeficiency
SCID) mice that lack adaptive immune responses and
hus permit xenografts of human PBMC. When PBMC
solated from HCV carriers were injected into SCID mice,
he presence and replication of HCV were detected over
ime in PBMC of grafted mice, supporting the persistent
eplication of HCV in PBMC.
Why is HCV infection/replication in PBMC, and specif-
cally lymphocytes, important for HCV pathogenesis from
biological and clinical point of view? HCV or its gene
roduct(s) may directly affect the function of immune
ells by interfering with their ability to clear HCV-infected
epatocytes. In light of our studies demonstrating that
he expression of HCV core protein facilitates the induc-
ion of Fas-mediated apoptosis in Jurkat T cell lines, the
CV core protein may play an important role in the
stablishment of HCV persistent infection. Although Fas-
ediated apoptosis is involved in downregulating nor-
al T cell responses, it may occur with increased sen-
itivity or at a lower threshold in the presence of HCV
ore protein. Therefore, the kinetics of activation-induced
poptosis may be facilitated. If the increased Fas-medi-
ted apoptosis induced by the core protein occurs in vivo
uring T cell activation, it might explain the high inci-
ence of persistence during natural HCV infection in
umans, presumably due to inefficient CTL activity.
Furthermore, the dysfunction in apoptosis may be
HCV CORE PROTEIN ASinked to development of HCC in chronic HCV patients
Saito et al., 1990). Although the development of HCC in
p
rhronic HCV patients may be due to potential oncogenic
roperties of HCV gene products, an impairment in im-
une surveillance cannot be ruled out for its role in the
evelopment of HCC. If the suppression of T cell re-
ponses to viral infection occurs as a result of HCV
nfection in T lymphocytes, their ability of tumor surveil-
ance would be greatly diminished. Further investiga-
ions of HCV core protein on the mechanism of T cell
ysfunction would clarify many of these questions.
In summary, the HCV core protein increased Fas-
ediated apoptosis of human T lymphocytes, presum-
bly mediated by the physical interaction between the
ore and the cytoplasmic domain of Fas. Further analysis
f the effect of the core protein on the Fas-mediated
ownstream signaling event suggests that the increased
poptosis of T lymphocytes is due to the upregulation of
aspase-3 activation. Currently, we are in the process of
xamining a detailed molecular mechanism for augmen-
ation of the downstream Fas signaling event induced by
he core protein.
MATERIALS AND METHODS
NA and plasmids
pCI:neo, pCDM8, pEGFP, and pGEX4T.3 plasmid DNA
ere purchased from Promega (Madison, WI), Clonetech
Palo Alto, CA), and Pharmacia Biotech (Piscataway, NJ),
espectively. Plasmid pCDM8/TNFR1 capable of ex-
ressing the cytoplasmic domain of the human TNFR1
amino acid residues 208 to 426) was a generous gift
rom Dr. T. H. Lee (Biotech Research Institute, Tae-Jeon,
orea) (Kim et al., 1995). Coding sequences of HCV core
erived from HCV Hutchinson strain (HCV-H, genotype
a) (Grakoui et al., 1993) were generated by juxtaposing
he appropriate HCV core coding sequence of amino
cid residues 1–192 in the pCI:neo plasmid followed by
translational termination codon in the plasmid. The
esulting plasmid construct was named pCI:core. The
pen reading frame of the core protein (a region of amino
cids 1 to 192) (Grakoui et al., 1993) was placed into
GEX4T.3 to generate a plasmid capable of expressing
ST fusion proteins and named pGEX:core.
Human Fas cDNA was placed under the control of the
hage T7 promoter in the pCDM8 plasmid. Extracellular
nd cytoplasmic domains of the Fas open reading frame
ere generated by PCR-based amplification of appropri-
te fragments encoding amino acid regions 1–171 and
90–335 of Fas, respectively. Oligonucleotides contain-
ng either a termination codon, 59-AGTGCTAGCTGGATC-
TTCCTCTTTG-39, or an initiation codon, 59-GTGAAGCT-
ATGGAAGTACAGAAAACATG-39, were used for PCR
mplification to generate extracellular and cytoplasmic
omains of Fas, respectively. All mutagenesis products
ere confirmed by DNA sequencing. Resulting PCR
133ULATOR OF APOPTOSISroducts representing the extracellular or cytoplasmic
egion of Fas were inserted into plasmid pCI:neo to
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N ETproduce radiolabeled protein by in vitro transcription and
translation.
Cell lines and transfection
Jurkat and HUT 78 T cells were obtained from the
American Type Culture Collection (Rockville, MD) and
maintained in RPMI 1640 medium (Gibco BRL, Gaithers-
burg, MD) supplemented with 10% (vol/vol) fetal bovine
serum (Gibco BRL) and 2 mM glutamine (Sigma Chemi-
cals Co., St. Louis, MO). L cell transfectants, L:FasL1,
nd L:FasL2 were generous gifts from Dr. J. H. Russell
(Washington University, St. Louis, MO) (Wang et al., 1996).
These L cell transfectants, P815, and BSC40 cells were
maintained in DMEM (Gibco BRL) supplemented with
10% fetal bovine serum and 2 mM glutamine.
Jurkat or HUT78 cells (1.2 3 107 cells/0.5 ml) were
ransfected with 10 mg of either pCI:neo vector alone or
CI:core or pEGFP using electroporation at 250 V, 800 mF
Cell Porator, Gibco BRL). For generation of stable trans-
ectants, Jurkat cells transfected with plasmid DNA were
aintained in medium containing G148 (0.5 mg/ml) and
ublines expressing the HCV core protein were estab-
ished by limiting dilution (Yokoyama, 1994). The expres-
ion of HCV core protein was confirmed by RT-PCR
nalysis. The level of cell surface expression of Fas in
urkat and its transfectants was examined by flow cytom-
try after staining cells with a murine anti-human Fas
onoclonal antibody (DX2) and a secondary antibody,
ITC-conjugated goat anti-mouse antibody.
51Cr-release assay for Fas-mediated cytotoxicity
Transiently-transfected Jurkat cells were labeled with
50 mCi 51Cr for 1 h and plated in a 96-well plate with 2 3
104 cells/well. Two groups of 51Cr-labeled target cells
were cocultured with either L:FasL1 or L:FasL2 cells at
an effector to target ratio of 1:3. One group was incu-
bated for 6 h and another group was incubated for 12 h.
After 6 and 12 h of incubation of cocultured cells, super-
natants were harvested and 51Cr release was deter-
ined. The percentage of specific lysis was calculated
y 100 3 (specific lysis-spontaneous lysis)/(total lysis-
pontaneous lysis).
accinia-virus-specific CTL response and virus
itration in lpr mice
Four- to 6-week-old lpr mice of B10.D2 genetic back-
round were obtained from Dr. Thomas J. Braciale (Uni-
ersity of Virginia, Charlottesville, VA). Mice were inocu-
ated intraperitoneally with 5 3 107 pfu of the recombi-
nant VV, vHCV-S, vHCV-C, and vSC11. vHCV-S and
vHCV-C express the HCV structural proteins (core, E1,
E2) and core protein, respectively. vSC11 is a parental
134 HAHrecombinant virus. On day 5 postinoculation, mice were
sacrificed and spleens were harvested. The primary vac-
h
ccinia-virus-specific CTL response was determined by
testing the ability of purified splenocytes from infected
mice upon lysing the VV-infected P815 target cells. At
autopsy, liver tissue was harvested to measure VV titers
on BSC40 cells followed by a previously described
method (Large et al., 1999).
Western blot analysis
Jurkat and its transfectants were collected, washed
with PBS (20 mM NaPO4, pH 7.5, 150 mM NaCl), lysed in
RIPA buffer (50 mM Tris.Cl, pH 7.5, 150 mM NaCl, 1 mM
EGTA, 0.5% Nonidet P-40, 0.5% deoxycholate, 1 mM 4-(2-
aminoethyl)-benzenesulfonyl fluoride, 0.3 mm aprotinin,
and 1 mM leupeptin), and separated by 12% SDS–PAGE.
Proteins were transferred onto either nitrocellulose
(Schleicher & Schuell, Keene, NH) or Immobilon polyvi-
nylidene difluoride (Millipore, Bedford, MA) membranes.
Membranes were blocked for more than 1 h in PBS
containing 2% nonfat milk and 0.25% Tween 20 and then
immunoblotted using HCV-core-specific rabbit anti-HCV
peptide 716 polyclonal antibody (American Qualex, San
Clemente, CA). Immunoreactive bands were detected
using horseradish-peroxidase-conjugated secondary an-
tibodies in conjunction with an enhanced chemilumines-
cent system (Pharmacia Biotech).
For analyzing caspase-3 activation by Western blot,
Jurkat and its stable transfectants were cultured to the
density of 8 3 105 cells/ml. Cells were collected and
esuspended in culture medium at a concentration of 5 3
05 cells/ml. Cells (106) were placed in a six-well tissue
ulture plate containing a monolayer of L:FasL1 or
L:FasL2. The effector (L:FasL1 or L:FasL2) to target
Jurkat and its transfectants) ratio was 1:3. To facilitate
ell-to-cell contact, plates were centrifuged at 100g rcf
or 5 min and placed in a 37°C incubator for specified
imes. Western blot analysis was performed as de-
cribed above to detect caspase-3 activation using
ouse monoclonal antibody against caspase-3 (Santa
ruz Biotechnology, Santa Cruz, CA).
aspase-3 enzyme assay
To measure the caspase-3 enzymatic activity, 2 3 106
Jurkat transfectants were coincubated with 106 cells of
either L:FasL2 or L:FasL1 cells in six-well clusters for
iven times at 37°C. Jurkat transfectants were collected,
ashed with PBS, and lysed in 100 mM NaCl, 50 mM
EPES, 10 mM dithiothreitol (DTT), 1 mM EDTA, 10%
lycerol, 0.1% CHAPS (pH 7.4), for 45 min on ice. Lysates
ere centrifuged to remove cell debris and incubated
ith 0.2 mM colorimetric caspase-3 substrate (Ac-DEVD-
NA) at 37°C. As a positive control, 10 U of purified
AL.uman recombinant caspase-3 was used. The activity of
aspase-3 was measured by reading the plate at 405 nm.
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A REGGST fusion protein binding assay
Glutathione thiotransferase and GST–core fusion pro-
tein (GST–core) were expressed in Escherichia coli
DH5a after transforming E. coli with plasmids pGEX4T
and pGEX:core. GST and GST–core were purified using
glutathione–agarose beads (Sigma) in accordance with
the supplier’s recommendation. [35S]Methionine-labeled
HCV core (full-length), Fas, and the cytoplasmic domain
of TNFR1 were generated using a coupled transcription–
translation rabbit reticulocyte lysate TNT system from
Promega with pCI:core, pCDM8:Fas, and pCDM8:TNFR1
plasmid DNA as templates, respectively. A total of 200 ng
of GST or GST–core coupled to 20 ml of glutathione–
garose beads (50% slurry) was incubated at 4°C with
35S]methionine-labeled core, Fas, and the cytoplasmic
omain of TNFR1 in 600 ml of a buffer solution containing
40 mM HEPES–KOH, pH 7.5, 150 mM KCl, 0.5 mM EDTA,
5 mM MgCl2, 1 mM DTT, 1 mM phenylmethylsulfonyl
fluoride, and 0.1% Nonidet P-40 for 1 h. To minimize
potential bead loss during subsequent washes, the
buffer was mixed with glutathione–agarose beads to
adjust to a total bead volume of 20 ml per reaction.
ollowing incubation, the beads were washed five times
ith the same buffer. The bound proteins were eluted
ith SDS–PAGE loading buffer and separated by SDS–
AGE and autoradiography.
Far-Western” protein blotting assay
The GST and GST–core proteins, partially purified us-
ng glutathione–agarose resin, were separated by 12%
DS–PAGE and electrotransferred to a nitrocellulose
embrane. GST–core protein has a tendency to be dis-
ociated into GST and core protein alone. The mem-
rane was washed with buffer A (10 mM HEPES, pH 7.5,
0 mM KCl, 1 mM EDTA, 1 mM DTT) and incubated with
M guanidium chloride for 10 min at 4°C and then
equentially with 2.5, 1.25, 0.625, 0.31, 0.15, and 0.08 M
uanidium chloride for 5 min each to renature the pro-
eins. The membrane was subsequently blocked with 5%
onfat milk in buffer A. Radiolabeled proteins, described
n the previous section, were then incubated with the
embrane in buffer A containing 5% nonfat milk. Un-
ound proteins were removed by washing the mem-
rane three times with buffer A containing 1% nonfat milk
nd 0.05% Nonidet P-40, and the bound proteins were
isualized by autoradiography.
T-PCR analysis for core-specific gene expression
Total RNA was prepared from Jurkat cells or Jurkat
ransfectants with Trizol (Gibco BRL) following the man-
facturer’s protocol. PBMC were purified by Isopaque
icoll gradient from HCV-infected patient’s blood and
HCV CORE PROTEIN ASNA was isolated as described above. For RT-PCR anal-
sis, random primed cDNA was synthesized from iso-ated total RNA using reverse transcriptase (Perkin–
lmer, Foster City, CA) according to the recommenda-
ions of the manufacturer. A portion of cDNA was used
or PCR in a volume of 50 ml using 0.5 U Taq polymerase
nd reagents obtained from Perkin–Elmer. HCV-core-
pecific primers (59 primer: 59-AAGAAAAACCAAACG-
AACACCA-39, region of nucleotides 365 to 387, 39
rimer: 59-CCAGCTAGG-CCGGAGAGCCACG-39, anti-
ense region of nucleotides 641 to 662) were used for
mplifying the cDNA encoding the HCV core protein.
poptosis assay by DNA content analysis
Cellular DNA contents were analyzed by flow cytom-
try according to a method previously described (Moor-
an et al., 1996). In brief, Jurkat and its stable transfec-
ants were cultured to a density of 8 3 105 cells/ml. Cells
ere collected and resuspended in medium at a con-
entration of 5 3 105 cells/ml and 5 3 105 were placed in
24-well tissue culture plate containing L cell transfec-
ants at a designated effector (L:FasL1 or L:FasL2) to
arget (Jurkat and its transfectants) ratio. To facilitate
ell-to-cell contact, plates were centrifuged at 100g rcf
or 5 min and placed in a 37°C incubator for the desig-
ated times. Jurkat cells and its stable transfectants
ere collected, washed with PBS, and resuspended in a
taining solution containing 50 mg/ml propidium iodide,
0.3% Nonidet P-40, 100 mg/ml boiled RNase A, and 0.1%
sodium citrate. Stained cells were placed at 4°C for at
least 30 min to eliminate RNA and analyzed with a
Becton–Dickinson FACSCalibur. DNA contents of cells
were analyzed with Becton–Dickinson Cell Quest soft-
ware and cells containing less than diploid DNA con-
tents were defined as an apoptotic cell population. An
average of 104 cells was analyzed in each sample and
most assays were performed in triplicate. To examine the
specificity of Fas-mediated apoptosis, Jurkat and its
transfectants expressing core protein were pretreated
with either caspase-3 inhibitor (100 nM Ac-DEVD-CHO in
1% DMSO Cal Biochem) or caspase-8 inhibitor (100 nM
Ac-IETD-CHO in 1% DMSO, Cal Biochem) or 1% DMSO
alone for 10 min at room temperature. The induction of
apoptosis was measured as described above.
Apoptosis induction by etoposide and 5-FU
Jurkat and its transfectants (106 log phase) expressing
core protein were treated with 0.1% methyl alcohol (ves-
icle), 0.33, 1, 3.3, and 10 mM of etoposide for 24 h. Cells
were harvested by centrifugation and the induction of
apoptosis was measured as described above. To exam-
ine the effect of 5-FU, 106 log phase Jurkat and its trans-
fectants expressing core protein were treated with mock,
3.3, 10, 33, or 100 mM 5-FU for 48 h. Cells were harvested
135ULATOR OF APOPTOSISby centrifugation and the induction of apoptosis was
measured as described above.
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